targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000258947 | MONDO_0001187 | NCT04383743 | Suspended | 2 | 2020-11-24 | Suspended | stopped | null | null | Phase II+ | 523,986,010,892 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00478361 | Completed | 2 | 2007-04-01 | null | null | null | null | Phase II+ | 523,986,012,139 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00478361 | Completed | 2 | 2007-04-01 | null | null | null | null | Phase II+ | 523,986,012,139 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00478361 | Completed | 2 | 2007-04-01 | null | null | null | null | Phase II+ | 523,986,012,139 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00478361 | Completed | 2 | 2007-04-01 | null | null | null | null | Phase II+ | 523,986,012,139 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00478361 | Completed | 2 | 2007-04-01 | null | null | null | null | Phase II+ | 523,986,012,139 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00478361 | Completed | 2 | 2007-04-01 | null | null | null | null | Phase II+ | 523,986,012,139 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00478361 | Completed | 2 | 2007-04-01 | null | null | null | null | Phase II+ | 523,986,012,139 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00478361 | Completed | 2 | 2007-04-01 | null | null | null | null | Phase II+ | 523,986,012,139 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00478361 | Completed | 2 | 2007-04-01 | null | null | null | null | Phase II+ | 523,986,012,139 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00478361 | Completed | 2 | 2007-04-01 | null | null | null | null | Phase II+ | 523,986,012,139 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00478361 | Completed | 2 | 2007-04-01 | null | null | null | null | Phase II+ | 523,986,012,139 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00478361 | Completed | 2 | 2007-04-01 | null | null | null | null | Phase II+ | 523,986,012,139 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003565 | Completed | 2 | 1998-09-01 | null | null | null | null | Phase II+ | 558,345,749,631 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003565 | Completed | 2 | 1998-09-01 | null | null | null | null | Phase II+ | 558,345,749,631 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003565 | Completed | 2 | 1998-09-01 | null | null | null | null | Phase II+ | 558,345,749,631 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003565 | Completed | 2 | 1998-09-01 | null | null | null | null | Phase II+ | 558,345,749,631 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003565 | Completed | 2 | 1998-09-01 | null | null | null | null | Phase II+ | 558,345,749,631 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003565 | Completed | 2 | 1998-09-01 | null | null | null | null | Phase II+ | 558,345,749,631 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003565 | Completed | 2 | 1998-09-01 | null | null | null | null | Phase II+ | 558,345,749,631 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003565 | Completed | 2 | 1998-09-01 | null | null | null | null | Phase II+ | 558,345,749,631 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003565 | Completed | 2 | 1998-09-01 | null | null | null | null | Phase II+ | 558,345,749,631 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003565 | Completed | 2 | 1998-09-01 | null | null | null | null | Phase II+ | 558,345,749,631 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003565 | Completed | 2 | 1998-09-01 | null | null | null | null | Phase II+ | 558,345,749,631 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003565 | Completed | 2 | 1998-09-01 | null | null | null | null | Phase II+ | 558,345,749,631 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00136175 | Completed | 2 | 1999-11-01 | null | null | null | null | Phase II+ | 618,475,291,648 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00136175 | Completed | 2 | 1999-11-01 | null | null | null | null | Phase II+ | 618,475,291,648 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00136175 | Completed | 2 | 1999-11-01 | null | null | null | null | Phase II+ | 618,475,291,648 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00136175 | Completed | 2 | 1999-11-01 | null | null | null | null | Phase II+ | 618,475,291,648 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00136175 | Completed | 2 | 1999-11-01 | null | null | null | null | Phase II+ | 618,475,291,648 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00136175 | Completed | 2 | 1999-11-01 | null | null | null | null | Phase II+ | 618,475,291,648 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00136175 | Completed | 2 | 1999-11-01 | null | null | null | null | Phase II+ | 618,475,291,648 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00136175 | Completed | 2 | 1999-11-01 | null | null | null | null | Phase II+ | 618,475,291,648 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00136175 | Completed | 2 | 1999-11-01 | null | null | null | null | Phase II+ | 618,475,291,648 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00136175 | Completed | 2 | 1999-11-01 | null | null | null | null | Phase II+ | 618,475,291,648 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00136175 | Completed | 2 | 1999-11-01 | null | null | null | null | Phase II+ | 618,475,291,648 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00136175 | Completed | 2 | 1999-11-01 | null | null | null | null | Phase II+ | 618,475,291,648 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00635726 | Terminated | 2 | 2008-02-01 | Terminated | stopped | null | null | Phase II+ | 773,094,114,644 | Due to poor accrual | Phase 2 | 29/02/2008 | Terminated | 08/10/2015 | 28/02/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00635726 | Terminated | 2 | 2008-02-01 | Terminated | stopped | null | null | Phase II+ | 773,094,114,644 | Due to poor accrual | Phase 2 | 29/02/2008 | Terminated | 08/10/2015 | 28/02/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00635726 | Terminated | 2 | 2008-02-01 | Terminated | stopped | null | null | Phase II+ | 773,094,114,644 | Due to poor accrual | Phase 2 | 29/02/2008 | Terminated | 08/10/2015 | 28/02/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00635726 | Terminated | 2 | 2008-02-01 | Terminated | stopped | null | null | Phase II+ | 773,094,114,644 | Due to poor accrual | Phase 2 | 29/02/2008 | Terminated | 08/10/2015 | 28/02/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00635726 | Terminated | 2 | 2008-02-01 | Terminated | stopped | null | null | Phase II+ | 773,094,114,644 | Due to poor accrual | Phase 2 | 29/02/2008 | Terminated | 08/10/2015 | 28/02/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00635726 | Terminated | 2 | 2008-02-01 | Terminated | stopped | null | null | Phase II+ | 773,094,114,644 | Due to poor accrual | Phase 2 | 29/02/2008 | Terminated | 08/10/2015 | 28/02/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00635726 | Terminated | 2 | 2008-02-01 | Terminated | stopped | null | null | Phase II+ | 773,094,114,644 | Due to poor accrual | Phase 2 | 29/02/2008 | Terminated | 08/10/2015 | 28/02/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00635726 | Terminated | 2 | 2008-02-01 | Terminated | stopped | null | null | Phase II+ | 773,094,114,644 | Due to poor accrual | Phase 2 | 29/02/2008 | Terminated | 08/10/2015 | 28/02/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00635726 | Terminated | 2 | 2008-02-01 | Terminated | stopped | null | null | Phase II+ | 773,094,114,644 | Due to poor accrual | Phase 2 | 29/02/2008 | Terminated | 08/10/2015 | 28/02/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00635726 | Terminated | 2 | 2008-02-01 | Terminated | stopped | null | null | Phase II+ | 773,094,114,644 | Due to poor accrual | Phase 2 | 29/02/2008 | Terminated | 08/10/2015 | 28/02/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00635726 | Terminated | 2 | 2008-02-01 | Terminated | stopped | null | null | Phase II+ | 773,094,114,644 | Due to poor accrual | Phase 2 | 29/02/2008 | Terminated | 08/10/2015 | 28/02/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00635726 | Terminated | 2 | 2008-02-01 | Terminated | stopped | null | null | Phase II+ | 773,094,114,644 | Due to poor accrual | Phase 2 | 29/02/2008 | Terminated | 08/10/2015 | 28/02/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002919 | Completed | 2 | 1996-11-01 | null | null | null | null | Phase II+ | 910,533,067,342 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002919 | Completed | 2 | 1996-11-01 | null | null | null | null | Phase II+ | 910,533,067,342 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002919 | Completed | 2 | 1996-11-01 | null | null | null | null | Phase II+ | 910,533,067,342 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002919 | Completed | 2 | 1996-11-01 | null | null | null | null | Phase II+ | 910,533,067,342 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002919 | Completed | 2 | 1996-11-01 | null | null | null | null | Phase II+ | 910,533,067,342 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002919 | Completed | 2 | 1996-11-01 | null | null | null | null | Phase II+ | 910,533,067,342 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002919 | Completed | 2 | 1996-11-01 | null | null | null | null | Phase II+ | 910,533,067,342 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002919 | Completed | 2 | 1996-11-01 | null | null | null | null | Phase II+ | 910,533,067,342 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002919 | Completed | 2 | 1996-11-01 | null | null | null | null | Phase II+ | 910,533,067,342 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002919 | Completed | 2 | 1996-11-01 | null | null | null | null | Phase II+ | 910,533,067,342 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002919 | Completed | 2 | 1996-11-01 | null | null | null | null | Phase II+ | 910,533,067,342 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00002919 | Completed | 2 | 1996-11-01 | null | null | null | null | Phase II+ | 910,533,067,342 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028860 | Completed | 2 | 2001-10-01 | null | null | null | null | Phase II+ | 953,482,739,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028860 | Completed | 2 | 2001-10-01 | null | null | null | null | Phase II+ | 953,482,739,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028860 | Completed | 2 | 2001-10-01 | null | null | null | null | Phase II+ | 953,482,739,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028860 | Completed | 2 | 2001-10-01 | null | null | null | null | Phase II+ | 953,482,739,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028860 | Completed | 2 | 2001-10-01 | null | null | null | null | Phase II+ | 953,482,739,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028860 | Completed | 2 | 2001-10-01 | null | null | null | null | Phase II+ | 953,482,739,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028860 | Completed | 2 | 2001-10-01 | null | null | null | null | Phase II+ | 953,482,739,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028860 | Completed | 2 | 2001-10-01 | null | null | null | null | Phase II+ | 953,482,739,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028860 | Completed | 2 | 2001-10-01 | null | null | null | null | Phase II+ | 953,482,739,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028860 | Completed | 2 | 2001-10-01 | null | null | null | null | Phase II+ | 953,482,739,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028860 | Completed | 2 | 2001-10-01 | null | null | null | null | Phase II+ | 953,482,739,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00028860 | Completed | 2 | 2001-10-01 | null | null | null | null | Phase II+ | 953,482,739,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022191 | Completed | 3 | 2001-05-01 | null | null | null | Phase III+ | Phase II+ | 970,662,609,947 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022191 | Completed | 3 | 2001-05-01 | null | null | null | Phase III+ | Phase II+ | 970,662,609,947 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022191 | Completed | 3 | 2001-05-01 | null | null | null | Phase III+ | Phase II+ | 970,662,609,947 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022191 | Completed | 3 | 2001-05-01 | null | null | null | Phase III+ | Phase II+ | 970,662,609,947 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022191 | Completed | 3 | 2001-05-01 | null | null | null | Phase III+ | Phase II+ | 970,662,609,947 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022191 | Completed | 3 | 2001-05-01 | null | null | null | Phase III+ | Phase II+ | 970,662,609,947 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022191 | Completed | 3 | 2001-05-01 | null | null | null | Phase III+ | Phase II+ | 970,662,609,947 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022191 | Completed | 3 | 2001-05-01 | null | null | null | Phase III+ | Phase II+ | 970,662,609,947 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022191 | Completed | 3 | 2001-05-01 | null | null | null | Phase III+ | Phase II+ | 970,662,609,947 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022191 | Completed | 3 | 2001-05-01 | null | null | null | Phase III+ | Phase II+ | 970,662,609,947 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022191 | Completed | 3 | 2001-05-01 | null | null | null | Phase III+ | Phase II+ | 970,662,609,947 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00022191 | Completed | 3 | 2001-05-01 | null | null | null | Phase III+ | Phase II+ | 970,662,609,947 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005047 | Terminated | 3 | 1997-08-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,005,022,347,570 | Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis. | Phase 3 | 31/08/1997 | Terminated | 08/06/2017 | 31/12/2014 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005047 | Terminated | 3 | 1997-08-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,005,022,347,570 | Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis. | Phase 3 | 31/08/1997 | Terminated | 08/06/2017 | 31/12/2014 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005047 | Terminated | 3 | 1997-08-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,005,022,347,570 | Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis. | Phase 3 | 31/08/1997 | Terminated | 08/06/2017 | 31/12/2014 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005047 | Terminated | 3 | 1997-08-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,005,022,347,570 | Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis. | Phase 3 | 31/08/1997 | Terminated | 08/06/2017 | 31/12/2014 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005047 | Terminated | 3 | 1997-08-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,005,022,347,570 | Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis. | Phase 3 | 31/08/1997 | Terminated | 08/06/2017 | 31/12/2014 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005047 | Terminated | 3 | 1997-08-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,005,022,347,570 | Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis. | Phase 3 | 31/08/1997 | Terminated | 08/06/2017 | 31/12/2014 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005047 | Terminated | 3 | 1997-08-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,005,022,347,570 | Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis. | Phase 3 | 31/08/1997 | Terminated | 08/06/2017 | 31/12/2014 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005047 | Terminated | 3 | 1997-08-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,005,022,347,570 | Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis. | Phase 3 | 31/08/1997 | Terminated | 08/06/2017 | 31/12/2014 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005047 | Terminated | 3 | 1997-08-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,005,022,347,570 | Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis. | Phase 3 | 31/08/1997 | Terminated | 08/06/2017 | 31/12/2014 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005047 | Terminated | 3 | 1997-08-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,005,022,347,570 | Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis. | Phase 3 | 31/08/1997 | Terminated | 08/06/2017 | 31/12/2014 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005047 | Terminated | 3 | 1997-08-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,005,022,347,570 | Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis. | Phase 3 | 31/08/1997 | Terminated | 08/06/2017 | 31/12/2014 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005047 | Terminated | 3 | 1997-08-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,005,022,347,570 | Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis. | Phase 3 | 31/08/1997 | Terminated | 08/06/2017 | 31/12/2014 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00315237 | Completed | 3 | 2005-07-01 | null | null | null | Phase III+ | Phase II+ | 1,039,382,087,511 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00315237 | Completed | 3 | 2005-07-01 | null | null | null | Phase III+ | Phase II+ | 1,039,382,087,511 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00315237 | Completed | 3 | 2005-07-01 | null | null | null | Phase III+ | Phase II+ | 1,039,382,087,511 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |